Individuals with breast and ovarian cancer susceptibility gene 1 (BRCA1) or BRCA2 germline mutations have a significantly increased lifetime risk for breast and ovarian cancers. BRCA-mutant cancer cells have abnormal homologous recombination (HR) repair of DNA. In these tumors, the base excision repair (BER) pathway is important for cell survival. The poly(adenosine diphosphate-ribose) polymerase (PARP) enzymes play a key role in BER, and PARP inhibitors are effective in causing cell death in BRCA-mutant cells while sparing normal cells-a concept called synthetic lethality. PARP inhibitors are the first cancer therapeutics designed to exploit synthetic lethality. Recent clinical trials in BRCA-mutant, metastatic breast cancer demonstrated improved outcomes with single-agent PARP inhibitors (olaparib and talazoparib) over chemotherapy. However, resistance to PARP inhibitors remains a challenge. Primarily due to myelosuppression, the combination of PARP inhibitors with chemotherapy has been difficult. Novel combinations with chemotherapy, immunotherapy, and other targeted therapies are being pursued. In this review, the authors discuss current knowledge of PARP inhibitors in BRCA-mutant breast cancer and potential future directions for these agents. Cancer 2018;124:2498-506. V C 2018 American Cancer Society.
evidence to suggest a role of PARP in restarting stalled DNA-fork replication and BRCA1/BRCA2-mediated homologous recombination. 16 When PARP is inhibited, single-strand breaks persist and result in stalled replication forks and doublestrand breaks. PARP function is impeded by PARP inhibitors (PARPis), resulting in catalytic inhibition, and some also trap PARP on DNA. These PARP-DNA complexes interfere with DNA replication, and recent studies have indicated that PARP trapping is important for the cytotoxicity of PARPis. 17 BRCA-mutant tumors develop HR deficiency secondary to germline mutation in 1 allele and loss of heterozygosity, inactivating the other copy. Treatment of these tumors with a PARPi leads to an accumulation of DNA damage, resulting in cell-cycle arrest and apoptosis. [18] [19] [20] This effect of PARP inhibition in cells that have defects in the HR pathway is an example of synthetic lethality (Fig. 1) . Increased PARP activity is also one of the mechanisms by which tumor cells avoid apoptosis caused by DNA-damaging chemotherapy agents, which normally would be repaired through the BER system. Therefore, the inhibition of PARP sensitizes tumor cells to cytotoxic agents, such as alkylators and topoisomerase I inhibitors. 21, 22 CLINICAL DEVELOPMENT IN BREAST CANCER Several PARPis are being studied in BRCA-mutant breast cancer. The clinical application of PARPis has progressed under 2 strategies: PARPi monotherapy in malignancies with impaired DNA-damage repair pathways and PARPis combined with DNA-damaging chemotherapy. Currently, 5 PARPis are being investigated in clinical trials. These include olaparib, rucaparib, niraparib, talazoparib, and veliparib (Table 1) . 23 Initially, another agentiniparib-was developed as a PARPi. However, after negative results from a phase 3 trial of iniparib combined with platinum and gemcitabine chemotherapy for metastatic TNBC, studies demonstrated that iniparib does not inhibit PARP in vitro. 24, 25 PARPis differ in their potency for catalytic inhibition and their ability to trap PARP. PARP trapping does not correlate with the potency of PARP enzyme inhibition. Of the available PARPis, talazoparib is the most potent catalytic inhibitor (it is approximately 100 times more potent than niraparib). 17 Talazoparib is the most potent in PARP trapping; however, rucaparib, olaparib, and niraparib also achieve PARP trapping. 17, 26 Although PARP trapping with veliparib has been reported, it appears to be the weakest at this mechanism. 26, 27 These differences in potency and trapping ability may be predictors of PARPi cytotoxicity in BRCA-mutant malignancies. Talazoparib reportedly has the most profound effect, but data are needed to determine whether this leads to improved clinical outcomes. 28 Increased cytotoxicity from PARP trapping also may increase toxicities, including cytopenias, thereby limiting the single agent maximum tolerated dose and combinations with chemotherapy. 27 
Single-Agent PARPis in Metastatic Breast Cancer
The initial phase 1 trial of olaparib enriched with carriers of BRCA mutations demonstrated promising early results, in which 47% of patients who had any BRCA-mutant malignancy achieved a partial response. 29 One of the 3 patients with BRCA-mutant breast cancer in that trial had a complete response lasting more than 60 weeks on olaparib 200 mg twice daily. It is noteworthy that no response was observed in any patients without BRCA mutations. Several early phase studies with the other PARPis demonstrated similar signals of efficacy in BRCAmutant breast cancer ( Table 2) . [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] Multiple phase 2 studies further demonstrated activity of olaparib in patients who had metastatic breast cancer with germline BRCA mutations. [30] [31] [32] In a phase 2 study, Tutt et al investigated the effects of olaparib monotherapy in 54 patients who had centrally confirmed, germline BRCA-mutant breast cancer. The patients received olaparib (either 400 mg or 100 mg) twice daily. 30 The primary endpoint of overall response rate (ORR) was 22% in the 100 mg cohort and 41% in the 400 mg cohort.
Similarly, phase 2 studies of talazoparib have demonstrated activity in patients with germline BRCA-mutant breast cancer. The phase 2 ABRAZO trial studied the use of talazoparib (1 mg daily) in 2 cohorts: 1) patients with BRCA-mutant, metastatic breast cancer who responded to platinum-chemotherapy with disease progression >8 weeks after the last dose of platinum therapy; and 2) patients who progressed on at least 3 systemic regimens but had no history of platinum-chemotherapy exposure. 38 The ORR was 26% in patients with TNBC and 29% in those with hormone receptor-positive, HER2-positive or HER2-negative disease. It is noteworthy that an increased time from the last platinum dose in cohort 1 correlated with improved ORR and progression-free survival (PFS). Several other ongoing phase 2 and 3 trials are studying PARPi monotherapy in advanced disease. [48] [49] [50] The activity of olaparib ultimately was confirmed in the phase 3 OlympiAD trial, which compared olaparib versus single agent chemotherapy in metastatic breast cancer. 33 Patients with HER2-negative, germline BRCAmutant breast cancer who had received no more than 2 prior chemotherapy treatments for metastatic cancer were randomized at a 2:1 ratio to receive either olaparib (300 mg twice daily) or physician's choice of chemotherapy (capecitabine, eribulin, or vinorelbine). The primary endpoint of median PFS was significantly longer in the olaparib group than in the chemotherapy group (7.0 vs 4.2 months; hazard ratio, 0.58; 95% confidence interval [CI], 0.43-0.80; P < .001). The response rate was nearly 60% in the olaparib group versus 28.8% in the control arm. There was no difference in overall survival (OS) between the olaparib and control arms (19.3 vs 19.6 months, respectively), likely because of the high degree of crossover. In the subgroup analysis, patients with TNBC were more likely to benefit from olaparib (hazard ratio, 0.43; 95% CI, 0.29-0.63). Conversely, patients with hormonereceptor positive breast cancers did not benefit statistically from olaparib (hazard ratio, 0.82; 95% CI, 0.55-1.26). Of note, patients in OlympiAD who had previously received platinum chemotherapy (28%) were less likely to benefit from olaparib therapy (hazard ratio, 0.67; 95% CI, 0.48-1.14), suggesting an overlap in the mechanisms of resistance. The rate of grade 3 or greater adverse events was lower in the olaparib group than in the standard therapy group (36.6% and 50.5%, respectively). The toxicities of olaparib are similar to those of other PARPis, the most common of which are anemia, nausea/vomiting, diarrhea, and fatigue. Overall, patient-reported qualityof-life metrics (the European Organization for Research and Treatment of Cancer Core 30 Quality-of-Life Recently, the activity of talazoparib in BRCAmutant breast cancer was demonstrated in the phase 3 EMBRACA trial. 39 Initial results from that trial demonstrated a median PFS of 8.6 months in patients who received talazoparib compared with 5.6 months in those who received chemotherapy (P < .0001). In addition, the ORR in the talazoparib group was more than twice that of the control arm (62.6% vs 27.2% for chemotherapy; P < .0001). This benefit from talazoparib was consistent across subgroups, including hormone receptor status, BRCA mutation status, prior chemotherapy, and history of central nervous system metastases.
PARPis in Combination With Chemotherapy in Metastatic Breast Cancer
It has been demonstrated that PARP inhibition sensitizes tumor cells to DNA-damaging therapies, including platinums, temozolomide, and radiation. 21, 22 Given these preclinical data, several clinical trials are studying combination therapy with the goal of potentiating the effect of cytotoxic chemotherapy (Table 2) . 34, 35, [42] [43] [44] [45] [46] [47] 51 In particular, veliparib has been explored as part of combination therapy. In a dose escalation study of veliparib plus carboplatin and paclitaxel in patients with advanced solid tumors, promising activity was observed, with an ORR of 57% in the breast cancer cohort. Additional phase 1 data from patients with breast cancer established the recommended phase 2 dose of veliparib as 150 mg twice daily (on days 22 to 15) with carboplatin (area under the curve 2) and paclitaxel (80 mg/m 2 ) on days 1, 8, and 15. 46 Because of myelosuppression, this dose is lower than the single agent maximum tolerated dose. The subsequent randomized phase 2 BROCADE trial studied the combination of veliparib and temozolomide or carboplatin/paclitaxel in patients with platinum-naive, BRCA-mutant, metastatic breast cancer. 47 Nearly 78% of patients in that trial who received veliparib combined with carboplatin/paclitaxel responded to treatment versus an ORR of 61% to the chemotherapy regimen alone. However, median PFS and OS did not meet the threshold for a statistically significant improvement. Grade 3 and 4 adverse events occurred in 34.4% and 27.1% of patients in the veliparib and placebo arms, respectively, and the most common toxicities were hematologic. Results from the veliparib/temozolomide arm of that trial have not been presented. The international phase 3 BROCADE trial studying the carboplatin/paclitaxel with or without veliparib combination is ongoing.
Clinical Development in Early Stage Disease
Given the successful development of PARPis in metastatic BRCA-mutant breast cancer, trials are underway to study their role in early stage disease in both the neoadjuvant and adjuvant settings. The I-SPY 2 trial is a multicenter, randomized phase 2 platform with multiple experimental arms adding novel agents or combinations to standard neoadjuvant chemotherapy with a primary endpoint of pathologic complete response (pCR). 52 Patients with TNBC were randomized to receive veliparib (50 mg twice daily on days 1-21) with carboplatin and paclitaxel versus paclitaxel alone for 4 cycles. All patients then received 4 cycles of doxorubicin and cyclophosphamide (AC) followed by primary breast surgery. An estimated pCR rate of 52% (95% CI, 36%-66%) was observed in the investigational veliparib/carboplatin arm versus 26% (95% CI, 9%-43%) in the standard treatment arm (paclitaxel followed by AC). The use of pCR as the primary endpoint has been associated with improved event-free survival in breast cancer. 53 It is notable that results based on germline BRCA mutation status have not been reported for this cohort. This promising activity is the basis for the phase 3 Brightness Study, which randomized patients with stage II and III TNBC to add carboplatin plus veliparib, carboplatin alone, or placebo to standard neoadjuvant paclitaxel chemotherapy followed by AC. 54 This study demonstrated an improved pCR in patients who received paclitaxel, carboplatin, and veliparib compared to paclitaxel (53% vs 31%, P < .0001). However, the addition of veliparib to carboplatin and paclitaxel did not improve pCR (58%, P 5 .36) compared to carboplatin and paclitaxel alone. Additionally, patients with BRCA-mutant breast cancer did not benefit from the addition of veliparib with carboplatin and paclitaxel. Of note this cohort only represented 15% of the study population and thus was not adequately powered to analyze this subgroup.
Neoadjuvant talazoparib monotherapy has demonstrated promising activity in a pilot phase 2 study. Thirteen patients who had BRCA-mutant breast cancer received 2 months of talazoparib monotherapy, which resulted in 88% (range 30%-98%) median tumor shrinkage by ultrasound. 55 The study was halted early to allow for the expansion of neoadjuvant talazoparib as the only treatment before surgery to assess for the pCR rate. 56 The phase 3 OlympiA study will assess the safety and efficacy of up to 12 months of adjuvant olaparib (300 mg twice daily) versus placebo in patients with BRCA-mutant TNBC or hormone receptor-positive/ HER2-negative breast cancer. 57 Patients must have completed definitive local treatment and neoadjuvant/adjuvant chemotherapy. Randomization will be stratified by hormone receptor status, prior neoadjuvant versus adjuvant chemotherapy, and prior receipt of platinum chemotherapy. The post-neoadjuvant treatment group will include patients who did not achieve pCR. The primary endpoint is invasive disease-free survival with secondary endpoints of OS, distant disease-free survival, and the development of new primary malignancies as well as safety and tolerability. Olaparib is also being studied in the neoadjuvant setting in combination with platinum-based chemotherapy for basal TNBC and BRCA-mutant breast cancer. 58 Finally, rucaparib is being tested in a phase 2 trial as adjuvant treatment with cisplatin in patients who have TNBC and BRCA-mutant breast cancer with residual disease after receiving anthracycline and/or taxane neoadjuvant therapy. 59 Patients were randomized to cisplatin with or without rucaparib for 24 weeks. Preliminary data demonstrated a significant improvement in 2-year disease-free survival with rucaparib and cisplatin (69.9% vs 55.9%, respectively; P 5 .04) in patients who received an anthracycline-containing regimen. It is noteworthy that BRCA mutation status did not impact disease-free survival.
RESISTANCE TO PARP INHIBITION
Like other targeted therapies, malignancies can acquire resistance to PARPi therapy. One proposed mechanism is restoration of the HR-repair pathway. There is evidence that the increased genomic instability promoted by PARP inhibition can lead to reversion mutations, leading to restoration of BRCA1/BRCA2 function and PARP resistance. 60 Other mechanisms of HR-repair restoration include loss of DNA-repair proteins p53 binding protein 1 (53BP1) and REV7. 61, 62 A second mechanism of resistance is increased drug efflux, leading to a reduction in PARPi intracellular concentration through the up-regulation of P-glycoprotein expression. 29 Finally, changes in PARP1 expression levels in cancer cells also lead to resistance to PARPis. Elevation of PARP1 mediates resistance to PARPis and is related to worse outcomes in patients with breast cancer. 63, 64 Some of these resistance mechanisms are shared between PARPis and platinum chemotherapy, although the degree of overlap is not clear. 65 The resistance mechanisms in platinum-resistant disease may limit the clinical utility of PARPis after platinum chemotherapy, and additional strategies to overcome acquired resistance will be needed. Notably, most ongoing studies of PARPis exclude patients who have platinum-resistant disease.
EXPANDING CLINICAL APPLICATION FOR PARP INHIBITORS
The antitumor activity observed with PARPis in BRCAmutant breast and ovarian cancers has demonstrated synthetic lethality as a therapeutic strategy. There are emerging data on the efficacy of PARPis in other BRCA-mutant malignancies, including prostate and pancreatic cancers. 32 It remains to be determined whether this can be expanded into other tumor types with deficiencies in DNA-repair mechanisms without BRCA1/BRCA2 germline mutations. Investigation has expanded in malignancies with the "BRCAness" phenotype. The term "BRCAness" refers to malignancies that have not arisen from germline BRCA1 or BRCA2 mutations but nonetheless share the phenotypic and molecular features of HR-repair deficiency because of a different genetic signature. 66 This includes somatic mutation in either BRCA1 or BRCA2, promoter hypermethylation of BRCA1, or mutations in other genes involved in double-stranded break DNA repair (ataxia-telangiectasia mutated [ATM], RAD51, PALB2, Fanconi anemia complementation group [FANC], phosphatase and tensin homolog [PTEN] ). 66 These malignancies share the same therapeutic vulnerabilities with BRCA-associated tumors, including sensitivity to platinum chemotherapy. 67, 68 There is no standardized biomarker of "BRCAness" currently available. Significant effort has been made to develop classifiers of "BRCAness" to help predict susceptibility to PARP inhibition. [68] [69] [70] [71] Recently, Severson et al developed a 77-gene signature to help define "BRCAness" and to investigate its ability to predict response to veliparib and carboplatin neoadjuvant therapy within the I-SPY2 clinical trial. 72 Although the trial was limited by a small sample size, the authors demonstrated an association between the "BRCAness" classification and patient response observed in the verliparib/carboplatin arm. Studies also are evaluating a HR deficiency score to help identify "BRCAness" by summing 3 different measures of genomic instability (loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions). 73 A positive score, defined as >42, was able to identify patients who were more responsive to platinum chemotherapy. There are ongoing studies expanding on this hypothesis with other PARPis, including rucaparib and talazoparib. 49, 74 Other strategies to extend the role of PARP inhibition in BRCA-mutant breast cancer include phosphoinositide 3-kinase (PI3K) inhibition. In addition to its role in proproliferative and antiapoptotic functions, the PI3K/MAPK pathway contributes to the repair of double-stranded DNA breaks in tumor cells. 75 In preclinical breast cancer models, the combination of a PI3K inhibitor and olaparib delayed tumor growth in mouse models, suggesting that combined inhibition of both PI3K and PARP might be effective treatment for BRCA-mutant malignancies. 75 Preliminary clinical efficacy has been demonstrated by Matulonis et al, who studied a combination of olaparib with the PI3K inhibitor BKM120 in patients with ovarian cancer or TNBC and reported an ORR of 24% (10 of 42 patients). 76 Finally, combinations of PARPis with immunotherapies, including antibodies to cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) and programmed death 1/ programmed death-ligand 1 (PD1/PD-L1) are being clinically investigated. Tumors with HR deficiency have higher genomic instability, and this may be associated with an elevated neoantigen load, which, in turn, has been associated with a stronger antitumor immune response. 77, 78 This combination rationale is also supported by preclinical evidence that immune therapy may be enhanced with PARPis. 79 In addition, there is evidence that tumors with DNA-repair deficiency may induce a stimulator of interferon genes (STING)-dependent, innate immune response in a cell cycle-specific manner. 80 In an early phase 1 trial, Lee et al studied the combination of durvalumab with olaparib or an antiangiogenesis agent cediranib in advanced female solid malignancies. 81 Among 12 evaluable patients who received durvalumab and olaparib, 2 had a partial response, and 8 had stable disease for >4 months, yielding a disease control rate of 83%. On the basis of this emerging evidence, there are ongoing trials studying the combination of PARPis with PD-L1 inhibitors. 82, 83 CONCLUSIONS PARP inhibition is an emerging strategy for the treatment of BRCA-mutant breast cancer. With the recent OlympiAD data, PARPis have been identified as an agent for consideration in patients who have metastatic disease. PARPis should be considered in particular for women who have BRCA-mutant TNBC based on the improved outcomes and lack of other targeted therapy options. Future directions will include optimizing combination therapy with chemotherapy, other targeted therapies, and immunotherapies, understanding and overcoming resistance mechanisms, and expanding the application of PARPis beyond BRCA-mutant breast cancer, particularly in malignancies with "BRCAness."
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